Profitability
Weight: 15%
D-
30
- 5yr Avg ROIC -7.6%
- Operating Margin Trend +1820.03 pp/yr
TGTX
TG Therapeutics, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 2 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
3
- 5yr Avg ROE -2.7%
- 5yr Share-Count CAGR 5.1%
Growth Quality
Weight: 35%
A+
96
- 5yr Revenue CAGR 209.8%
- 5yr EPS CAGR 469.9%
- Revenue-Growth Years (5) 4/5
Cash Generation
Weight: 20%
F
0
- 5yr FCF Margin -2156.3%
- 5yr FCF/NI Conversion -1.42x
Balance Sheet
Weight: 10%
A-
82
- Net Debt / EBITDA 0.88x
- Interest Coverage (EBIT/Int) 5.02x
- Altman Z-Score 4.34
Stability
Weight: 5%
D
33
- EPS Volatility (σ/μ) 1.53
- Piotroski F-Score 4
- Negative-Revenue Years (5) 1/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 4 gurus held; 3 trimmed; 1 full exit.
- Holders
- 3 -1
- Avg Δ position
- -16.5%
- New buys
- 0
- Full exits
- 1